JP7618597B2 - Ｄ１ポジティブアロステリックモジュレーターとしての置換されたテトラヒドロイソキノリン誘導体 - Google Patents
Ｄ１ポジティブアロステリックモジュレーターとしての置換されたテトラヒドロイソキノリン誘導体 Download PDFInfo
- Publication number
- JP7618597B2 JP7618597B2 JP2021575050A JP2021575050A JP7618597B2 JP 7618597 B2 JP7618597 B2 JP 7618597B2 JP 2021575050 A JP2021575050 A JP 2021575050A JP 2021575050 A JP2021575050 A JP 2021575050A JP 7618597 B2 JP7618597 B2 JP 7618597B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- methyl
- pharma
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183641 | 2019-07-01 | ||
| EP19183641.0 | 2019-07-01 | ||
| PCT/EP2020/068181 WO2021001286A1 (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537994A JP2022537994A (ja) | 2022-08-31 |
| JP2022537994A5 JP2022537994A5 (https=) | 2023-07-04 |
| JP7618597B2 true JP7618597B2 (ja) | 2025-01-21 |
Family
ID=67137842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575050A Active JP7618597B2 (ja) | 2019-07-01 | 2020-06-29 | Ｄ１ポジティブアロステリックモジュレーターとしての置換されたテトラヒドロイソキノリン誘導体 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US12358890B2 (https=) |
| EP (1) | EP3993795B1 (https=) |
| JP (1) | JP7618597B2 (https=) |
| KR (1) | KR102949226B1 (https=) |
| CN (1) | CN114008032B (https=) |
| AR (1) | AR119317A1 (https=) |
| AU (1) | AU2020299705B2 (https=) |
| BR (1) | BR112021022379A2 (https=) |
| CA (1) | CA3139622A1 (https=) |
| CL (1) | CL2021002949A1 (https=) |
| CO (1) | CO2021017740A2 (https=) |
| EC (1) | ECSP22007557A (https=) |
| IL (1) | IL289317B2 (https=) |
| MA (1) | MA56445A (https=) |
| MX (1) | MX2021015872A (https=) |
| MY (1) | MY210362A (https=) |
| PE (1) | PE20220373A1 (https=) |
| PH (1) | PH12021552819A1 (https=) |
| SA (1) | SA521431274B1 (https=) |
| SG (1) | SG11202112539XA (https=) |
| TW (1) | TWI842923B (https=) |
| UA (1) | UA130613C2 (https=) |
| WO (1) | WO2021001286A1 (https=) |
| ZA (1) | ZA202109194B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2976784T3 (es) | 2020-10-07 | 2024-08-08 | Lilly Co Eli | Derivados de fenil-3,4-dihidroisoquinolin-2(1H)-il-etan-1-ona como moduladores alostéricos positivos del receptor de dopamina D1 |
| EP4304577A1 (en) * | 2021-03-09 | 2024-01-17 | Eli Lilly And Co. | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017530185A (ja) | 2014-10-08 | 2017-10-12 | ユーシービー バイオファルマ エスピーアールエル | テトラヒドロイソキノリン誘導体 |
| JP2019513792A (ja) | 2016-04-13 | 2019-05-30 | ユーシービー バイオファルマ エスピーアールエル | テトラヒドロイソキノリン誘導体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2679735A1 (en) | 2007-03-01 | 2008-09-12 | Janssen Pharmaceutica N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
| KR101284796B1 (ko) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스 |
| IN2014CN03234A (https=) | 2011-11-03 | 2015-07-03 | Merck Sharp & Dohme | |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| JP7090099B2 (ja) * | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
-
2020
- 2020-06-29 IL IL289317A patent/IL289317B2/en unknown
- 2020-06-29 CN CN202080043673.9A patent/CN114008032B/zh active Active
- 2020-06-29 CA CA3139622A patent/CA3139622A1/en active Pending
- 2020-06-29 BR BR112021022379A patent/BR112021022379A2/pt unknown
- 2020-06-29 SG SG11202112539XA patent/SG11202112539XA/en unknown
- 2020-06-29 MX MX2021015872A patent/MX2021015872A/es unknown
- 2020-06-29 PE PE2021002217A patent/PE20220373A1/es unknown
- 2020-06-29 EP EP20735361.6A patent/EP3993795B1/en active Active
- 2020-06-29 WO PCT/EP2020/068181 patent/WO2021001286A1/en not_active Ceased
- 2020-06-29 US US17/621,871 patent/US12358890B2/en active Active
- 2020-06-29 JP JP2021575050A patent/JP7618597B2/ja active Active
- 2020-06-29 KR KR1020227002603A patent/KR102949226B1/ko active Active
- 2020-06-29 MA MA056445A patent/MA56445A/fr unknown
- 2020-06-29 UA UAA202106080A patent/UA130613C2/uk unknown
- 2020-06-29 AU AU2020299705A patent/AU2020299705B2/en active Active
- 2020-06-29 MY MYPI2021006863A patent/MY210362A/en unknown
- 2020-06-29 PH PH1/2021/552819A patent/PH12021552819A1/en unknown
- 2020-06-30 TW TW109122034A patent/TWI842923B/zh active
- 2020-06-30 AR ARP200101852A patent/AR119317A1/es unknown
-
2021
- 2021-11-08 CL CL2021002949A patent/CL2021002949A1/es unknown
- 2021-11-17 ZA ZA2021/09194A patent/ZA202109194B/en unknown
- 2021-12-23 CO CONC2021/0017740A patent/CO2021017740A2/es unknown
- 2021-12-30 SA SA521431274A patent/SA521431274B1/ar unknown
-
2022
- 2022-01-31 EC ECSENADI20227557A patent/ECSP22007557A/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017530185A (ja) | 2014-10-08 | 2017-10-12 | ユーシービー バイオファルマ エスピーアールエル | テトラヒドロイソキノリン誘導体 |
| JP2019513792A (ja) | 2016-04-13 | 2019-05-30 | ユーシービー バイオファルマ エスピーアールエル | テトラヒドロイソキノリン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3139622A1 (en) | 2021-01-07 |
| JP2022537994A (ja) | 2022-08-31 |
| IL289317B1 (en) | 2025-05-01 |
| EP3993795B1 (en) | 2026-04-22 |
| IL289317B2 (en) | 2025-09-01 |
| SG11202112539XA (en) | 2021-12-30 |
| IL289317A (en) | 2022-02-01 |
| ZA202109194B (en) | 2023-11-29 |
| TWI842923B (zh) | 2024-05-21 |
| MA56445A (fr) | 2022-05-11 |
| AU2020299705B2 (en) | 2026-03-19 |
| WO2021001286A1 (en) | 2021-01-07 |
| CN114008032B (zh) | 2023-11-10 |
| PH12021552819A1 (en) | 2022-09-28 |
| ECSP22007557A (es) | 2022-02-25 |
| AR119317A1 (es) | 2021-12-09 |
| SA521431274B1 (ar) | 2024-01-09 |
| CL2021002949A1 (es) | 2022-07-15 |
| KR102949226B1 (ko) | 2026-04-06 |
| US20220251064A1 (en) | 2022-08-11 |
| US12358890B2 (en) | 2025-07-15 |
| CO2021017740A2 (es) | 2022-01-17 |
| BR112021022379A2 (pt) | 2022-03-08 |
| PE20220373A1 (es) | 2022-03-16 |
| UA130613C2 (uk) | 2026-04-01 |
| TW202115009A (zh) | 2021-04-16 |
| CN114008032A (zh) | 2022-02-01 |
| AU2020299705A1 (en) | 2021-12-09 |
| KR20220029687A (ko) | 2022-03-08 |
| EP3993795A1 (en) | 2022-05-11 |
| MX2021015872A (es) | 2022-02-03 |
| MY210362A (en) | 2025-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7510444B2 (ja) | Ｄ１ポジティブアロステリックモジュレーターとしての置換テトラヒドロイソキノリン誘導体 | |
| EP3442945B1 (en) | Tetrahydroisoquinoline derivatives | |
| JP7618597B2 (ja) | Ｄ１ポジティブアロステリックモジュレーターとしての置換されたテトラヒドロイソキノリン誘導体 | |
| JP2023554033A (ja) | ジヒドロイソキノリニル誘導体 | |
| RU2824527C2 (ru) | Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1 | |
| JP2023551173A (ja) | オクタヒドロイソキノリニル誘導体 | |
| KR20230121849A (ko) | D1 포지티브 알로스테릭 모듈레이터로서 치환된 테트라하이드로이소퀴놀린유도체 | |
| HK40060812B (zh) | 作为d1正变构调节剂的取代的四氢异喹啉衍生物 | |
| HK40060812A (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| RU2824581C2 (ru) | Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1 | |
| HK40058931A (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| HK40058931B (zh) | 作为d1正变构调节剂的取代的四氢异喹啉衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230623 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230623 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240625 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241016 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241212 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250108 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7618597 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |